APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Synthetic Peptide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Synthetic Peptide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174039220330 December 2025198 pages

Choose your research edition.

Industry ResearchSynthetic Peptide Vaccine Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Synthetic Peptide Vaccine Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Synthetic Peptide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Synthetic Peptide Vaccine Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Synthetic Peptide Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Synthetic Peptide Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Synthetic Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Synthetic Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Synthetic Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Synthetic Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Synthetic Peptide Vaccine include Merck, Targovax, TapImmune, Sumitomo Dainippon Pharma, Spotlight Innovation, Pharmasyntez, Peptech, OncoTherapy Science and Lytix Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Synthetic Peptide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Synthetic Peptide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Synthetic Peptide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Synthetic Peptide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Synthetic Peptide Vaccine Segment by Company

Merck

Targovax

TapImmune

Sumitomo Dainippon Pharma

Spotlight Innovation

Pharmasyntez

Peptech

OncoTherapy Science

Lytix Biopharma

ISA Pharmaceuticals

ImmunoCellular Therapeutics

Immatics biotechnologies

Celgene Corporation

Benovus Bio

Artificial Cell Technologies

Apitope Technology

Antigen Express

Anergis

Synthetic Peptide Vaccine Segment by Type

Solution Phase Synthesis (SPS)

Solid Phase Peptide Synthesis (SPPS)

Synthetic Peptide Vaccine Segment by Application

Lung Cancer

Prostate Cancer

Breast Cancer

Gastric Cancer

Pancreatic Cancer

Others

Synthetic Peptide Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Synthetic Peptide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Synthetic Peptide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Synthetic Peptide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Synthetic Peptide Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Synthetic Peptide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Synthetic Peptide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Synthetic Peptide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Synthetic Peptide Vaccine Industry Trends Table 2. Synthetic Peptide Vaccine Industry Drivers Table 3. Synthetic Peptide Vaccine Industry Opportunities and Challenges Table 4. Synthetic Peptide Vaccine Industry Restraints Table 5. Global Synthetic Peptide Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Synthetic Peptide Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Synthetic Peptide Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Synthetic Peptide Vaccine Sales Market Share by Manufacturers Table 9. Global Synthetic Peptide Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Synthetic Peptide Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Synthetic Peptide Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Synthetic Peptide Vaccine Manufacturers, Product Type & Application Table 13. Global Synthetic Peptide Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Synthetic Peptide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Solution Phase Synthesis (SPS) Table 17. Major Manufacturers of Solid Phase Peptide Synthesis (SPPS) Table 18. Global Synthetic Peptide Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Synthetic Peptide Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Global Synthetic Peptide Vaccine Sales by Type (2027-2032) & (K Units) Table 21. Global Synthetic Peptide Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Synthetic Peptide Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Synthetic Peptide Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Synthetic Peptide Vaccine Revenue by Type (2021-2026) & (K Units) Table 25. Global Synthetic Peptide Vaccine Revenue by Type (2027-2032) & (K Units) Table 26. Global Synthetic Peptide Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Synthetic Peptide Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Lung Cancer Table 29. Major Manufacturers of Prostate Cancer Table 30. Major Manufacturers of Breast Cancer Table 31. Major Manufacturers of Gastric Cancer Table 32. Major Manufacturers of Pancreatic Cancer Table 33. Major Manufacturers of Others Table 34. Global Synthetic Peptide Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Synthetic Peptide Vaccine Sales by Application (2021-2026) & (K Units) Table 36. Global Synthetic Peptide Vaccine Sales by Application (2027-2032) & (K Units) Table 37. Global Synthetic Peptide Vaccine Sales Market Share by Application (2021-2026) Table 38. Global Synthetic Peptide Vaccine Sales Market Share by Application (2027-2032) Table 39. Global Synthetic Peptide Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Synthetic Peptide Vaccine Revenue by Application (2021-2026) & (K Units) Table 41. Global Synthetic Peptide Vaccine Revenue by Application (2027-2032) & (K Units) Table 42. Global Synthetic Peptide Vaccine Revenue Market Share by Application (2021-2026) Table 43. Global Synthetic Peptide Vaccine Revenue Market Share by Application (2027-2032) Table 44. Global Synthetic Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Synthetic Peptide Vaccine Sales by Region (2021-2026) & (K Units) Table 46. Global Synthetic Peptide Vaccine Sales Market Share by Region (2021-2026) Table 47. Global Synthetic Peptide Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Synthetic Peptide Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Synthetic Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Synthetic Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 51. North America Synthetic Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 52. Europe Synthetic Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Synthetic Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 54. Europe Synthetic Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Synthetic Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Synthetic Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Synthetic Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Synthetic Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Synthetic Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Synthetic Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 61. Global Synthetic Peptide Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Synthetic Peptide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Synthetic Peptide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Synthetic Peptide Vaccine Revenue Market Share by Region (2021-2026) Table 65. Global Synthetic Peptide Vaccine Revenue Market Share by Region (2027-2032) Table 66. Merck Company Information Table 67. Merck Business Overview Table 68. Merck Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Merck Synthetic Peptide Vaccine Product Portfolio Table 70. Merck Recent Development Table 71. Targovax Company Information Table 72. Targovax Business Overview Table 73. Targovax Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Targovax Synthetic Peptide Vaccine Product Portfolio Table 75. Targovax Recent Development Table 76. TapImmune Company Information Table 77. TapImmune Business Overview Table 78. TapImmune Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. TapImmune Synthetic Peptide Vaccine Product Portfolio Table 80. TapImmune Recent Development Table 81. Sumitomo Dainippon Pharma Company Information Table 82. Sumitomo Dainippon Pharma Business Overview Table 83. Sumitomo Dainippon Pharma Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Sumitomo Dainippon Pharma Synthetic Peptide Vaccine Product Portfolio Table 85. Sumitomo Dainippon Pharma Recent Development Table 86. Spotlight Innovation Company Information Table 87. Spotlight Innovation Business Overview Table 88. Spotlight Innovation Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Spotlight Innovation Synthetic Peptide Vaccine Product Portfolio Table 90. Spotlight Innovation Recent Development Table 91. Pharmasyntez Company Information Table 92. Pharmasyntez Business Overview Table 93. Pharmasyntez Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Pharmasyntez Synthetic Peptide Vaccine Product Portfolio Table 95. Pharmasyntez Recent Development Table 96. Peptech Company Information Table 97. Peptech Business Overview Table 98. Peptech Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Peptech Synthetic Peptide Vaccine Product Portfolio Table 100. Peptech Recent Development Table 101. OncoTherapy Science Company Information Table 102. OncoTherapy Science Business Overview Table 103. OncoTherapy Science Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. OncoTherapy Science Synthetic Peptide Vaccine Product Portfolio Table 105. OncoTherapy Science Recent Development Table 106. Lytix Biopharma Company Information Table 107. Lytix Biopharma Business Overview Table 108. Lytix Biopharma Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Lytix Biopharma Synthetic Peptide Vaccine Product Portfolio Table 110. Lytix Biopharma Recent Development Table 111. ISA Pharmaceuticals Company Information Table 112. ISA Pharmaceuticals Business Overview Table 113. ISA Pharmaceuticals Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. ISA Pharmaceuticals Synthetic Peptide Vaccine Product Portfolio Table 115. ISA Pharmaceuticals Recent Development Table 116. ImmunoCellular Therapeutics Company Information Table 117. ImmunoCellular Therapeutics Business Overview Table 118. ImmunoCellular Therapeutics Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. ImmunoCellular Therapeutics Synthetic Peptide Vaccine Product Portfolio Table 120. ImmunoCellular Therapeutics Recent Development Table 121. Immatics biotechnologies Company Information Table 122. Immatics biotechnologies Business Overview Table 123. Immatics biotechnologies Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Immatics biotechnologies Synthetic Peptide Vaccine Product Portfolio Table 125. Immatics biotechnologies Recent Development Table 126. Celgene Corporation Company Information Table 127. Celgene Corporation Business Overview Table 128. Celgene Corporation Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Celgene Corporation Synthetic Peptide Vaccine Product Portfolio Table 130. Celgene Corporation Recent Development Table 131. Benovus Bio Company Information Table 132. Benovus Bio Business Overview Table 133. Benovus Bio Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Benovus Bio Synthetic Peptide Vaccine Product Portfolio Table 135. Benovus Bio Recent Development Table 136. Artificial Cell Technologies Company Information Table 137. Artificial Cell Technologies Business Overview Table 138. Artificial Cell Technologies Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Artificial Cell Technologies Synthetic Peptide Vaccine Product Portfolio Table 140. Artificial Cell Technologies Recent Development Table 141. Apitope Technology Company Information Table 142. Apitope Technology Business Overview Table 143. Apitope Technology Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Apitope Technology Synthetic Peptide Vaccine Product Portfolio Table 145. Apitope Technology Recent Development Table 146. Antigen Express Company Information Table 147. Antigen Express Business Overview Table 148. Antigen Express Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Antigen Express Synthetic Peptide Vaccine Product Portfolio Table 150. Antigen Express Recent Development Table 151. Anergis Company Information Table 152. Anergis Business Overview Table 153. Anergis Synthetic Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Anergis Synthetic Peptide Vaccine Product Portfolio Table 155. Anergis Recent Development Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Synthetic Peptide Vaccine Distributors List Table 159. Synthetic Peptide Vaccine Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Synthetic Peptide Vaccine Product Image Figure 2. Global Synthetic Peptide Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Synthetic Peptide Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Synthetic Peptide Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Synthetic Peptide Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Synthetic Peptide Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Solution Phase Synthesis (SPS) Image Figure 9. Solid Phase Peptide Synthesis (SPPS) Image Figure 10. Global Synthetic Peptide Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Synthetic Peptide Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Synthetic Peptide Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Synthetic Peptide Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Synthetic Peptide Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Synthetic Peptide Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Lung Cancer Image Figure 17. Prostate Cancer Image Figure 18. Breast Cancer Image Figure 19. Gastric Cancer Image Figure 20. Pancreatic Cancer Image Figure 21. Others Image Figure 22. Global Synthetic Peptide Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Synthetic Peptide Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Synthetic Peptide Vaccine Sales Market Share by Application (2021-2032) Figure 25. Global Synthetic Peptide Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Synthetic Peptide Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Synthetic Peptide Vaccine Revenue Market Share by Application (2021-2032) Figure 28. North America Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Synthetic Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 30. U.S. Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Synthetic Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 35. Germany Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Synthetic Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 42. China Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Synthetic Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 50. Brazil Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Synthetic Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Synthetic Peptide Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Synthetic Peptide Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Synthetic Peptide Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. North America Synthetic Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Synthetic Peptide Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Europe Synthetic Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Synthetic Peptide Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Synthetic Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Synthetic Peptide Vaccine Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Synthetic Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Synthetic Peptide Vaccine Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Synthetic Peptide Vaccine Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Solution Phase Synthesis (SPS)
  • Solid Phase Peptide Synthesis (SPPS)
Applications
  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Gastric Cancer
  • Pancreatic Cancer
  • Others
Companies covered
  • Merck
  • Targovax
  • TapImmune
  • Sumitomo Dainippon Pharma
  • Spotlight Innovation
  • Pharmasyntez
  • Peptech
  • OncoTherapy Science
  • Lytix Biopharma
  • ISA Pharmaceuticals
  • ImmunoCellular Therapeutics
  • Immatics biotechnologies
  • Celgene Corporation
  • Benovus Bio
  • Artificial Cell Technologies
  • Apitope Technology
  • Antigen Express
  • Anergis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Synthetic Peptide Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Synthetic Peptide Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Synthetic Peptide Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Synthetic Peptide Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Synthetic Peptide Vaccine Market Dynamics
  1. 2.1 Synthetic Peptide Vaccine Industry Trends
  2. 2.2 Synthetic Peptide Vaccine Industry Drivers
  3. 2.3 Synthetic Peptide Vaccine Industry Opportunities and Challenges
  4. 2.4 Synthetic Peptide Vaccine Industry Restraints
3 Synthetic Peptide Vaccine Market by Manufacturers
  1. 3.1 Global Synthetic Peptide Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Synthetic Peptide Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Synthetic Peptide Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Synthetic Peptide Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Synthetic Peptide Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Synthetic Peptide Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Synthetic Peptide Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Synthetic Peptide Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Synthetic Peptide Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Synthetic Peptide Vaccine Tier 1, Tier 2, and Tier 3
4 Synthetic Peptide Vaccine Market by Type
  1. 4.1 Synthetic Peptide Vaccine Type Introduction
  2. 4.1.1 Solution Phase Synthesis (SPS)
  3. 4.1.2 Solid Phase Peptide Synthesis (SPPS)
  4. 4.2 Global Synthetic Peptide Vaccine Sales by Type
  5. 4.2.1 Global Synthetic Peptide Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Synthetic Peptide Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Synthetic Peptide Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Synthetic Peptide Vaccine Revenue by Type
  9. 4.3.1 Global Synthetic Peptide Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Synthetic Peptide Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Synthetic Peptide Vaccine Revenue Market Share by Type (2021-2032)
5 Synthetic Peptide Vaccine Market by Application
  1. 5.1 Synthetic Peptide Vaccine Application Introduction
  2. 5.1.1 Lung Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Gastric Cancer
  6. 5.1.5 Pancreatic Cancer
  7. 5.1.6 Others
  8. 5.2 Global Synthetic Peptide Vaccine Sales by Application
  9. 5.2.1 Global Synthetic Peptide Vaccine Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Synthetic Peptide Vaccine Sales by Application (2021-2032)
  11. 5.2.3 Global Synthetic Peptide Vaccine Sales Market Share by Application (2021-2032)
  12. 5.3 Global Synthetic Peptide Vaccine Revenue by Application
  13. 5.3.1 Global Synthetic Peptide Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Synthetic Peptide Vaccine Revenue by Application (2021-2032)
  15. 5.3.3 Global Synthetic Peptide Vaccine Revenue Market Share by Application (2021-2032)
6 Global Synthetic Peptide Vaccine Sales by Region
  1. 6.1 Global Synthetic Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Synthetic Peptide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Synthetic Peptide Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Synthetic Peptide Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Synthetic Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Synthetic Peptide Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Synthetic Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Synthetic Peptide Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Synthetic Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Synthetic Peptide Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Synthetic Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Synthetic Peptide Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Synthetic Peptide Vaccine Revenue by Region
  1. 7.1 Global Synthetic Peptide Vaccine Revenue by Region
  2. 7.1.1 Global Synthetic Peptide Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Synthetic Peptide Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Synthetic Peptide Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Synthetic Peptide Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Synthetic Peptide Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Synthetic Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Synthetic Peptide Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Synthetic Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Synthetic Peptide Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Synthetic Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Synthetic Peptide Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Synthetic Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Synthetic Peptide Vaccine Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Targovax
  8. 8.2.1 Targovax Company Information
  9. 8.2.2 Targovax Business Overview
  10. 8.2.3 Targovax Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Targovax Synthetic Peptide Vaccine Product Portfolio
  12. 8.2.5 Targovax Recent Developments
  13. 8.3 TapImmune
  14. 8.3.1 TapImmune Company Information
  15. 8.3.2 TapImmune Business Overview
  16. 8.3.3 TapImmune Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 TapImmune Synthetic Peptide Vaccine Product Portfolio
  18. 8.3.5 TapImmune Recent Developments
  19. 8.4 Sumitomo Dainippon Pharma
  20. 8.4.1 Sumitomo Dainippon Pharma Company Information
  21. 8.4.2 Sumitomo Dainippon Pharma Business Overview
  22. 8.4.3 Sumitomo Dainippon Pharma Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sumitomo Dainippon Pharma Synthetic Peptide Vaccine Product Portfolio
  24. 8.4.5 Sumitomo Dainippon Pharma Recent Developments
  25. 8.5 Spotlight Innovation
  26. 8.5.1 Spotlight Innovation Company Information
  27. 8.5.2 Spotlight Innovation Business Overview
  28. 8.5.3 Spotlight Innovation Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Spotlight Innovation Synthetic Peptide Vaccine Product Portfolio
  30. 8.5.5 Spotlight Innovation Recent Developments
  31. 8.6 Pharmasyntez
  32. 8.6.1 Pharmasyntez Company Information
  33. 8.6.2 Pharmasyntez Business Overview
  34. 8.6.3 Pharmasyntez Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pharmasyntez Synthetic Peptide Vaccine Product Portfolio
  36. 8.6.5 Pharmasyntez Recent Developments
  37. 8.7 Peptech
  38. 8.7.1 Peptech Company Information
  39. 8.7.2 Peptech Business Overview
  40. 8.7.3 Peptech Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Peptech Synthetic Peptide Vaccine Product Portfolio
  42. 8.7.5 Peptech Recent Developments
  43. 8.8 OncoTherapy Science
  44. 8.8.1 OncoTherapy Science Company Information
  45. 8.8.2 OncoTherapy Science Business Overview
  46. 8.8.3 OncoTherapy Science Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 OncoTherapy Science Synthetic Peptide Vaccine Product Portfolio
  48. 8.8.5 OncoTherapy Science Recent Developments
  49. 8.9 Lytix Biopharma
  50. 8.9.1 Lytix Biopharma Company Information
  51. 8.9.2 Lytix Biopharma Business Overview
  52. 8.9.3 Lytix Biopharma Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Lytix Biopharma Synthetic Peptide Vaccine Product Portfolio
  54. 8.9.5 Lytix Biopharma Recent Developments
  55. 8.10 ISA Pharmaceuticals
  56. 8.10.1 ISA Pharmaceuticals Company Information
  57. 8.10.2 ISA Pharmaceuticals Business Overview
  58. 8.10.3 ISA Pharmaceuticals Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 ISA Pharmaceuticals Synthetic Peptide Vaccine Product Portfolio
  60. 8.10.5 ISA Pharmaceuticals Recent Developments
  61. 8.11 ImmunoCellular Therapeutics
  62. 8.11.1 ImmunoCellular Therapeutics Company Information
  63. 8.11.2 ImmunoCellular Therapeutics Business Overview
  64. 8.11.3 ImmunoCellular Therapeutics Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 ImmunoCellular Therapeutics Synthetic Peptide Vaccine Product Portfolio
  66. 8.11.5 ImmunoCellular Therapeutics Recent Developments
  67. 8.12 Immatics biotechnologies
  68. 8.12.1 Immatics biotechnologies Company Information
  69. 8.12.2 Immatics biotechnologies Business Overview
  70. 8.12.3 Immatics biotechnologies Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Immatics biotechnologies Synthetic Peptide Vaccine Product Portfolio
  72. 8.12.5 Immatics biotechnologies Recent Developments
  73. 8.13 Celgene Corporation
  74. 8.13.1 Celgene Corporation Company Information
  75. 8.13.2 Celgene Corporation Business Overview
  76. 8.13.3 Celgene Corporation Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Corporation Synthetic Peptide Vaccine Product Portfolio
  78. 8.13.5 Celgene Corporation Recent Developments
  79. 8.14 Benovus Bio
  80. 8.14.1 Benovus Bio Company Information
  81. 8.14.2 Benovus Bio Business Overview
  82. 8.14.3 Benovus Bio Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Benovus Bio Synthetic Peptide Vaccine Product Portfolio
  84. 8.14.5 Benovus Bio Recent Developments
  85. 8.15 Artificial Cell Technologies
  86. 8.15.1 Artificial Cell Technologies Company Information
  87. 8.15.2 Artificial Cell Technologies Business Overview
  88. 8.15.3 Artificial Cell Technologies Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Artificial Cell Technologies Synthetic Peptide Vaccine Product Portfolio
  90. 8.15.5 Artificial Cell Technologies Recent Developments
  91. 8.16 Apitope Technology
  92. 8.16.1 Apitope Technology Company Information
  93. 8.16.2 Apitope Technology Business Overview
  94. 8.16.3 Apitope Technology Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Apitope Technology Synthetic Peptide Vaccine Product Portfolio
  96. 8.16.5 Apitope Technology Recent Developments
  97. 8.17 Antigen Express
  98. 8.17.1 Antigen Express Company Information
  99. 8.17.2 Antigen Express Business Overview
  100. 8.17.3 Antigen Express Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Antigen Express Synthetic Peptide Vaccine Product Portfolio
  102. 8.17.5 Antigen Express Recent Developments
  103. 8.18 Anergis
  104. 8.18.1 Anergis Company Information
  105. 8.18.2 Anergis Business Overview
  106. 8.18.3 Anergis Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Anergis Synthetic Peptide Vaccine Product Portfolio
  108. 8.18.5 Anergis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Synthetic Peptide Vaccine Value Chain Analysis
  2. 9.1.1 Synthetic Peptide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Synthetic Peptide Vaccine Production Mode & Process
  6. 9.2 Synthetic Peptide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Synthetic Peptide Vaccine Distributors
  9. 9.2.3 Synthetic Peptide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst